COVID-19 cases continue to escalate worldwide
The original announcement by the National Research Council of Canada is available at bit.ly/2JRa4fQ.
BOLD-100 is a first-in-class ruthenium-based small molecule drug which selectively inhibits stress-induced upregulation of the chaperone protein GRP78. Currently, the investigational treatment is in a Phase 1b clinical trial in gastrointestinal cancer. In cancer, GRP78 plays a critical role in resistance, survival and proliferation, whereas in viral infections, GRP78 plays a critical role in host recognition, viral entry and viral replication. Preclinical studies have repeatedly demonstrated BOLD-100 has a robust antiviral response against COVID-19. We are thankful to have this support from NRC IRAP to continue developing BOLD-100 as an antiviral stated Mark Bazett, PhD, Director of Preclinical Development of Bold Therapeutics. We look forward to completing the next required set of nonclinical and manufacturing studies so that we can
American Manganese Reviews 2020 Highlights phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Share this article
mRNA vaccine is first fully made-in-Canada vaccine to undergo trials
TORONTO and CALGARY, AB, Dec. 23, 2020 /CNW/ - Providence Therapeutics today announced that Health Canada has provided a Notice of Authorization for its Clinical Trial Application. This permits the Canadian biotech company to begin human clinical trials of its COVID-19 vaccine. PTX-COVID19-B is a messenger RNA (mRNA) vaccine and is the first fully made-in-Canada COVID vaccine to reach this stage of development.
Health Canada s authorization means Phase I clinical trials will begin early in the New Year. Later phase clinical trials are expected to proceed in 2021, subject to regulatory approval.
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
VANCOUVER, British Columbia, Dec. 18, 2020 Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to quickly move forward the potential application of Qu’s lung-directed SSI, QBKPN, to prevent and treat infection with SARS-CoV-2, the virus causing COVID-19. Unlike traditional vaccines that direct the host adaptive immune response to a very specific antigen, Qu’s immunotherapy platform engages and trains the innate arm of the
Published: Dec 18, 2020
OTTAWA, ON, Dec. 18, 2020 /CNW/ - The Government of Canada is aggressively pursuing the purchase and development of COVID-19 treatments and related supplies to protect Canadians and is working to strengthen Canada s biomanufacturing sector. This includes engaging with Canadian scientists, businesses and manufacturers to build Canada s capacity to fight COVID-19 and future pandemics.
Today, the National Research Council of Canada (NRC) announced it is providing advisory services and over $9 million in research and development funding through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support 4 therapeutic firms. These include:
Up to $289,032.00 to
Bold Therapeutics (Vancouver, BC) for a project to prepare preclinical efficacy data in live SARS-CoV-2 (COVID-19), support preparation for clinical trials, and to support manufacturing of its BOLD-100 investigational therapy to treat patients with viral